An Economic Evaluation of Rizatriptan in the Treatment of Migraine

Author： Thompson Melissa  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.23, Iss.8, 2005-01, pp. : 837-850

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rizatriptan: A Pharmacoeconomic Review of its Use in the Acute Treatment of Migraine

By McCormack Paul L.   Foster Rachel H.  

PharmacoEconomics, Vol. 23, Iss. 12, 2005-01 ,pp. : 1283-1298

Adis International

Access to resources Recommend Favorite

Cost-Effectiveness Analysis of Rizatriptan and Sumatriptan versus Cafergot ® in the Acute Treatment of Migraine

By Zhang Lihua   Hay Joel W.  

CNS Drugs, Vol. 19, Iss. 7, 2005-01 ,pp. : 635-642

Adis International

Access to resources Recommend Favorite

Spotlight on Rizatriptan in Migraine

By Wellington K.   Jarvis B.  

CNS Drugs, Vol. 16, Iss. 10, 2002-01 ,pp. : 715-720

Adis International

Access to resources Recommend Favorite

A review of rizatriptan, a quick and consistent 5-HT1B/1D agonist for the acute treatment of migraine

By Pascual Julio  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 3, 2004-03 ,pp. : 669-677

Informa Healthcare

Access to resources Recommend Favorite

Rizatriptan: a new 5-HT1B/1D receptor agonist for the treatment of migraine

By Dahlof C.   Lines C.  

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 5, 1999-05 ,pp. : 671-685

Informa Healthcare

Access to resources Recommend Favorite